Amniotic Membrane in Ophthalmology: Off-Label Evidence

Human amniotic membrane (AM) has been applied to the ocular surface for more than seven decades. Although the wound care field primarily uses AM for chronic cutaneous ulcers, burns, and surgical wounds, the same biological properties, anti-inflammatory signaling, basement membrane support, and neurotrophic factor content, have driven extensive off-label ophthalmic use. For podiatrists, wound care physicians, and orthopedic surgeons who collaborate with ophthalmology or manage patients with complex ocular surface disease, understanding the evidence base helps inform referral timing and interdisciplinary coordination.

Clinical Evidence in Ocular Surface Disease

The strongest published data support AM in three overlapping conditions: moderate-to-severe dry eye disease (DED), neurotrophic keratitis (NK) with persistent epithelial defects, and refractory corneal epithelial defects in cicatricial disease.

A pilot study by Cheng et al. in 10 patients with moderate-to-severe DED found symptom relief lasting a mean of 4.2 months after self-retained cryopreserved AM placement, along with reduced OSDI scores, conjunctival hyperemia, corneal staining, and topical medication burden.²

Neurotrophic keratitis and persistent epithelial defects. A 2020 review by Mead, Tighe, and Tseng pooled 162 eyes across prospective and retrospective series of cryopreserved AM transplantation for NK. Pooled epithelial healing rate was 88.9%, with mean time to epithelialization of 18.4 days; 52.3% of evaluable eyes gained more than two lines of vision, and the pooled recurrence rate was 6.8%.³

Cicatricial ocular surface disease. In four patients with ocular cicatricial pemphigoid, Stevens-Johnson syndrome, and toxic epidermal necrolysis, topical morselized cryopreserved AM combined with umbilical cord tissue produced complete epithelialization in a mean of 7.3 days and reduced ocular surface inflammation when conventional measures had failed.⁴

Mechanism of Action

AM is composed of an epithelial monolayer, a basement membrane rich in type IV and VII collagen, and an avascular stroma. The basement membrane promotes epithelial cell migration, adhesion, and differentiation, while the stroma contains heavy-chain hyaluronan/pentraxin 3 (HC-HA/PTX3), which has been shown to induce apoptosis of activated neutrophils, polarize macrophages toward an anti-inflammatory M2 phenotype, downregulate TGF-β signaling, and inhibit angiogenesis.³ Cryopreserved formulations also retain nerve growth factor and other trophic proteins that may support corneal nerve regeneration, a proposed mechanism for sustained symptom improvement beyond the period of membrane residence.^2,3

In-Office Application Protocol

Modern sutureless devices allow AM to be placed in the office rather than the operating room. The AAO pearls summary outlines a practical workflow:⁵

1. Confirm indication and rule out contraindications. Active microbial keratitis should be treated with appropriate antimicrobials before or concurrently with AM; descemetocele or perforation generally require surgical management.
2. Obtain informed consent. Discuss off-label status, expected temporary visual blur, mild foreign-body sensation, and rare intolerance requiring early removal.
3. Apply topical anesthetic. Insert the self-retained cryopreserved device like a large contact lens, or place a dehydrated membrane onto the ocular surface and cover with a bandage contact lens.
4. Leave in place 3 to 7 days. The membrane typically dissolves over one week; remove the retaining ring once the membrane has resorbed.
5. Continue concurrent topical therapy. Medication penetration is generally not impaired by AM.
6. Schedule follow-up. Document corneal staining, epithelial defect dimensions, visual acuity, and symptoms at 1 week, 1 month, and 3 months.

Cryopreserved vs. Dehydrated Amniotic Membrane

Two commercial categories are available for ophthalmic use. The choice affects storage, handling, reimbursement, and the strength of supporting evidence.

Feature	Cryopreserved AM	Dehydrated AM
Storage	-80°C freezer; thaw before use	Room temperature; rehydrate before use
Structure	Retains extracellular matrix, heavy-chain HA, growth factors	Devitalized cellular components; collagen scaffold
FDA-cleared claims	Protective, wound healing, anti-inflammatory (device)	Wound coverage
Delivery	Self-retained ring or sutured/sutureless patch	Disk applied under bandage contact lens
Evidence profile	Larger published series in DED, NK, persistent defects	Growing; more limited comparative data
Common products	PROKERA family (Bio-Tissue)	AmbioDisk, BioDOptix, Seed Biotech

Coding and Reimbursement Considerations

Ophthalmic AM is generally not billed through the same skin-substitute pathways used for diabetic foot or venous leg ulcers. Coding depends on technique and payer:

• Supply code V2790 is commonly used for amniotic membrane applied for ophthalmic indications.
• Surgical codes 65780 (conjunctival graft) or 65781 (amniotic membrane transplantation) may apply when AM is sutured in the operating room.
• Office placement of a self-retained device is often billed as a supply-only service or under an appropriate E/M visit; payer policies vary widely.

Because many ophthalmic indications remain off-label, prior authorization and robust documentation are essential. Records should show failed standard therapy (artificial tears, punctal plugs, topical cyclosporine or lifitegrast, bandage contact lens), medical necessity, pre- and post-treatment photographs, and objective measures such as corneal staining, tear break-up time, or DEWS severity.

Key Takeaways

• Published evidence supports off-label AM use in moderate-to-severe DED, neurotrophic keratitis, persistent epithelial defects, and acute cicatricial ocular surface disease.
• Cryopreserved AM has the strongest clinical dataset and retains biologically active matrix components; dehydrated AM offers room-temperature convenience with a narrower FDA claim set.
• Early intervention, before corneal melt or scarring, appears to improve visual and symptomatic outcomes.
• Active infection and impending perforation must be excluded or managed before placement.
• Documentation of failed standard therapy and objective severity measures is critical for reimbursement.